neurology
-
Artificial Intelligence, BioPharma
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.
-
Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds
Rapport Therapeutics, a clinical-stage biotech that was founded last year, raised $150 million in Series B financing, bringing its total funding to date to $250 million. The company’s platform leverages receptor-associated proteins to create neurology drugs that have more focused activity in the brain, going after disease-driving circuits and cell types.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
GrayMatters Health Earns FDA Clearance for PTSD Neuromodulation Device
GrayMatters Health recently received 510(k) clearance from the FDA to market its flagship product, which is a self-neuromodulation digital therapy for PTSD. The device uses neurofeedback on specific biomarkers to help patients identify and utilize their own mental strategy for lowering their emotional response.
-
Devices & Diagnostics, BioPharma
California dreamin’: A VC firm’s vision for West Coast-focused biotech investment
Red Tree Venture Capital has closed a $272 million fund focused on investing in West Coast life sciences companies. The firm’s founders say they’re filling a need by providing financial support for innovations emerging from the region’s academic labs.
-
Memory Health CEO shares approach to combating Alzheimer’s disease
Memory Health CEO Edward Shehab talked about taking a preventive approach to neurodegenerative conditions.
-
MindMaze fuels growth in gamified neurorehab with $105M in financing
The financing round was led by Concord Health Partners, with AlbaCore Capital Group and Hambro Perks also contributing. The latest haul follows a $125 million raise that the company announced in October.
-
Telemedicine, Artificial Intelligence, Health Tech
AI that flags urgent cases for radiologists gets FDA clearance
Nines received 510(k) clearance for a system that monitors CT scans for likely cases intracranial hemorrhage and mass effect, two conditions associated with strokes. The system prioritizes these cases for review from radiologists, letting patients receive a diagnosis faster.
-
Devices & Diagnostics, Health Tech
Insightec raises $150M for incisionless surgery
Insightec, a company making an ultrasound device that can be used to treat essential tremor, raised $150 million. The company now has a post-money valuation of $1.3 billion.
-
Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B
Alder, based in a suburb of Seattle, has a monoclonal antibody that it has investigated as a treatment for migraine and is under FDA review, with the agency expected to decide on its approval in February of next year. Shares of Alder were up 83 percent on the news.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
How best to describe precision medicine beyond oncology? ‘It’s complicated.’
While well-developed in cancers, precision medicine’s readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
-
Ovid Therapeutics starts Phase III trial in rare neurological disorder
The trial’s primary endpoint will be one for which the drug, OV101, produced encouraging but mixed results in a Phase II study of patients with Angelman syndrome.
-
Eisai appoints two execs to lead Alzheimer’s franchise
The move comes less than two months after the high-profile failure of aducanumab, which it had developed with Biogen, and the initiation a day later of a Phase III study of another amyloid beta-targeting drug, BAN 2401.
-
Failure of once-promising Alzheimer’s drug reinforces doubts about amyloid beta
Biogen halting its Phase III trial of aducanumab last month had many proclaiming the amyloid beta hypothesis’ demise. But many doctors soldier on, while others see potential alternative uses for Abeta-targeting drugs.
-
Neuraly launches with $36 million Series A to develop neurological disease drug
Nature Medicine mouse study shows once-weekly GLP-1 receptor agonist slowed Parkinson’s disease progression.
-
Appello Pharmaceuticals nets $10.5 million in Series A funding for Parkinson’s drugs
The company will use the funding to develop mGlu4 PAMs licensed from Vanderbilt University.